Albemarle Corporation (NYSE:ALB) was downgraded by research analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a research note issued to investors on Monday, Marketbeat reports. They currently have a $135.00 price objective on the specialty chemicals company’s stock, up from their previous price objective of $134.29. Robert W. Baird’s price objective would suggest a potential upside of 0.53% from the stock’s previous close. The analysts noted that the move was a valuation call.

Several other research analysts have also recently weighed in on ALB. KeyCorp raised their target price on Albemarle Corporation from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Monday, June 12th. Jefferies Group LLC reiterated a “buy” rating and issued a $120.00 price target on shares of Albemarle Corporation in a research report on Friday, June 16th. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price target on shares of Albemarle Corporation in a research report on Thursday, June 29th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $47.00 price target on shares of Albemarle Corporation in a research report on Thursday, June 29th. Finally, Zacks Investment Research upgraded Albemarle Corporation from a “hold” rating to a “buy” rating and set a $121.00 price target for the company in a research report on Friday, July 7th. Eight research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $113.17.

Albemarle Corporation (ALB) traded down 3.407% on Monday, hitting $129.715. The stock had a trading volume of 627,735 shares. The company has a market cap of $14.33 billion, a PE ratio of 16.590 and a beta of 1.61. Albemarle Corporation has a one year low of $76.32 and a one year high of $136.95. The stock has a 50-day moving average of $117.92 and a 200-day moving average of $111.37.

Albemarle Corporation (NYSE:ALB) last announced its earnings results on Monday, August 7th. The specialty chemicals company reported $1.13 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.11 by $0.02. Albemarle Corporation had a return on equity of 11.59% and a net margin of 31.49%. The business had revenue of $737.25 million during the quarter, compared to analysts’ expectations of $735.50 million. During the same quarter last year, the business posted $0.93 earnings per share. The company’s quarterly revenue was up 10.1% on a year-over-year basis. Equities analysts expect that Albemarle Corporation will post $4.37 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/25/albemarle-corporation-alb-rating-lowered-to-neutral-at-robert-w-baird.html.

In other news, CFO Scott Tozier sold 25,000 shares of the stock in a transaction dated Friday, July 7th. The stock was sold at an average price of $110.13, for a total transaction of $2,753,250.00. Following the transaction, the chief financial officer now owns 57,506 shares of the company’s stock, valued at approximately $6,333,135.78. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Matthew Juneau sold 5,397 shares of the stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $115.77, for a total value of $624,810.69. Following the transaction, the executive vice president now directly owns 360 shares in the company, valued at approximately $41,677.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 91,897 shares of company stock worth $10,215,486. 0.74% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Perigon Wealth Management LLC grew its holdings in Albemarle Corporation by 6.4% in the 2nd quarter. Perigon Wealth Management LLC now owns 7,046 shares of the specialty chemicals company’s stock valued at $746,000 after buying an additional 426 shares during the last quarter. W. E. Donoghue & Co. LLC acquired a new stake in Albemarle Corporation in the 2nd quarter valued at approximately $2,173,000. Lord Abbett & CO. LLC acquired a new stake in Albemarle Corporation in the 2nd quarter valued at approximately $11,681,000. USA Financial Portformulas Corp grew its holdings in Albemarle Corporation by 9.6% in the 2nd quarter. USA Financial Portformulas Corp now owns 30,985 shares of the specialty chemicals company’s stock valued at $3,270,000 after buying an additional 2,725 shares during the last quarter. Finally, Toronto Dominion Bank grew its holdings in Albemarle Corporation by 23.6% in the 2nd quarter. Toronto Dominion Bank now owns 37,565 shares of the specialty chemicals company’s stock valued at $3,964,000 after buying an additional 7,165 shares during the last quarter. 83.73% of the stock is currently owned by hedge funds and other institutional investors.

About Albemarle Corporation

Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions.

Analyst Recommendations for Albemarle Corporation (NYSE:ALB)

Receive News & Ratings for Albemarle Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle Corporation and related companies with MarketBeat.com's FREE daily email newsletter.